We read with interest the SARAH trial published in The Lancet Oncology.1 Two recently reported randomised controlled trials, the SARAH Trial1 and the SIRveNIb trial,2 were intended to show survival advantages comparing yttrium-90 (90Y) resin microsphere treatment with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Both trials have been negative. We herein discuss the concept that failure to show superiority does not mean 90Y is equivalent to sorafenib, as the conclusion of the SARAH trial might indicate.
http://ift.tt/2E1vlhL
Τετάρτη 31 Ιανουαρίου 2018
[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου